ArticleImmunity, inflammation and disease2025
The Unprecedented Influenza Epidemic of 2024/2025: Overshadowing the COVID-19 Winter Wave and Exploring Viral Interference.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Evaluation of Universal Biomolecular Medium for Molecular Detection of Respiratory Viruses: A Paired, Multi-Platform Comparison.Microorganisms · 2026Article
- Diagnosis of Respiratory Infections Using Syndromic Panels: A Ct-Based Approach Beyond Qualitative Detection.Microorganisms · 2026Article
- Epidemiological Characteristics and Co-Detection Patterns of Rhinovirus (A/B/C) and Influenza A Virus in a Regional Respiratory Cohort in Hunan, China.The clinical respiratory journal · 2026Article
- Article
- The Unprecedented Influenza Epidemic of 2024/2025: Overshadowing the COVID-19 Winter Wave and Exploring Viral Interference.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundIn winter 2024/2025, one of the most severe U.S. influenza epidemics since 2017, with 82 million illnesses and ~ 130,000 deaths, eclipsed a comparatively subdued SARS-CoV-2 wave (~ 20 million infections, ~540,000 hospitalizations, ~63,000 COVID-19 deaths), a hypothesis supported by existing CDC data and virological models. HYPOTHESIS: Influenza's robust interferon response might have contributed to suppression of SARS-CoV-2 replication, creating an antiviral environment that delayed COVID-19's winter surge. EVIDENCE: In vitro studies demonstrate influenza interference with SARS-CoV-2, reversible by oseltamivir, supporting this hypothesis. Thus, the decline in influenza activity in spring 2025 may have contributed to the observed increase in SARS-CoV-2 hospitalizations, driven by the NB.1.8.1 variant, a JN.1 derivative with enhanced transmissibility and reduced neutralization. Although this did not evolve into a pandemic-scale wave, the resultant burden on healthcare services was clinically meaningful. Alternative explanations, including behavioral changes and Omicron-induced herd immunity, are considered but less compelling. IMPLICATION: The global health implications are critical: lapsed COVID-19 preparedness, limited surveillance, and low vaccine uptake threaten effective responses. RECOMMANDATIONS: We advocate enhanced surveillance, adopting wastewater monitoring as demonstrated in the U.S., and integrated vaccination campaigns with combined influenza-COVID-19 vaccines, currently in phase III trials, to boost immunity. Resource allocation, informed by the 2024/2025 hospital overload, is essential to manage surges. This article underscores the need for global coordination to understand viral interference and prepare for shifting respiratory virus dynamics, offering actionable strategies to mitigate future epidemics, including those caused by other viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.